Calidi Biotherapeutics (CLDI) Liabilities and Shareholders Equity (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Liabilities and Shareholders Equity of $8.9 million for Q4 2025, down 37.55% year-over-year from $14.2 million in Q4 2024, and down 36.87% quarter-over-quarter from $14.0 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $8.9 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 37.55% year-over-year to $8.9 million; the TTM figure through Dec 2025 stood at $47.3 million (up 36.41% YoY), while the FY2025 annual figure was $8.9 million, down 37.55% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $8.9 million, down from $14.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $231.8 million in Q4 2021, with the low at $1.3 million in Q3 2023.
- The 5-year median for Liabilities and Shareholders Equity is $14.0 million (2025), against an average of $54.1 million.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity plunged 98.88% in 2022, then jumped 412.08% in 2024.
- Calidi Biotherapeutics' Liabilities and Shareholders Equity stood at $231.8 million in 2021, then slumped by 98.88% to $2.6 million in 2022, then soared by 285.79% to $10.0 million in 2023, then soared by 41.55% to $14.2 million in 2024, then tumbled by 37.55% to $8.9 million in 2025.
- Business Quant data shows CLDI's Liabilities and Shareholders Equity at $8.9 million in Q4 2025, $14.0 million in Q3 2025, and $9.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.20 Mn |
| Dec 31, 2025 | 8.86 Mn |
| Sep 30, 2025 | 14.03 Mn |
| Jun 30, 2025 | 9.35 Mn |
| Mar 31, 2025 | 15.06 Mn |
| Dec 31, 2024 | 14.18 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 6.43 Mn |
| Mar 31, 2024 | 7.41 Mn |
| Dec 31, 2023 | 10.02 Mn |
| Sep 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 44.01 Mn |
| Mar 31, 2023 | 43.18 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 42.16 Mn |
| Jun 30, 2022 | 231.02 Mn |
| Mar 31, 2022 | 231.24 Mn |
| Dec 31, 2021 | 231.77 Mn |